GlassScriptPhysician profile
Ghadeer N Hannoudi
NPI 1124095948
$7,730.48
in general payments reported to CMS, 2019-2025
28 companies · $980 in 2025
The $980 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $836 · 2020: $988 · 2021: $1,024 · 2022: $1,154 · 2023: $1,250 · 2024: $1,498 · 2025: $980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,500 · Education: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,499.90 |
| Education | $228.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,099.10 | 2019-2025 | Farxiga |
| Amgen INC. | $749.41 | 2019-2025 | Tavneos, Krystexxa, Uplizna |
| Vifor Pharma, INC. | $703.73 | 2019-2023 | Korsuva, Veltassa |
| Opko Pharmaceuticals, LLC | $673.36 | 2019-2024 | Rayaldee |
| Aurinia Pharma U.S., INC. | $534.39 | 2021-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $525.50 | 2019-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $435.17 | 2023-2025 | |
| Travere Therapeutics, INC. | $363.88 | 2021-2025 | |
| Horizon Therapeutics Plc | $352.60 | 2021-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $305.94 | 2020-2023 | Acthar |
| Otsuka America Pharmaceutical, INC. | $292.50 | 2019-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $240.36 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $222.10 | 2020-2023 | Benlysta, Jesduvroq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.13 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $186.96 | 2022-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $130.33 | 2019-2025 | Velphoro, Velphoro |
| Novo Nordisk INC | $120.51 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Akebia Therapeutics INC | $118.37 | 2019-2025 | Vafseo, Auryxia |
| Ardelyx, INC. | $106.59 | 2023-2025 | Ibsrela |
| Ultragenyx Pharmaceutical INC. | $78.44 | 2019-2021 | |
| Daiichi Sankyo INC. | $50.41 | 2019-2024 | Injectafer |
| Amag Pharmaceuticals, INC. | $46.17 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.68 | 2022-2023 | Gattex |
| Scpharmaceuticals INC. | $42.77 | 2025 | |
| Mallinckrodt Enterprises LLC | $32.98 | 2019 | |
| Alnylam Pharmaceuticals INC. | $25.96 | 2023 | Oxlumo |
| Ani Pharmaceuticals, INC. | $19.39 | 2024 | Purified Cortrophin Gel |
| Abbott Laboratories | $18.75 | 2023 | Jeti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghadeer Hannoudi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.